NACDS Foundation names beneficiaries of Community PREP grant program
ALEXANDRIA, Va. — Purdue University, the University of Missouri and the University of North Carolina were the beneficiaries of a $1.5 million grant program designed to expand community pharmacy residency programs for recent school graduates.
The National Association of Chain Drug Stores Foundation announced on Thursday that the academic institutions were the first three beneficiaries of the Community Pharmacy Residency Expansion Project (Community PREP) grant program.
For this first round of awards, the recipients were:
Purdue University, with practice sites at Kroger;
University of Missouri – Kansas City, with practice sites at Red Cross Pharmacy; and
University of North Carolina, with practices sites at Kerr Drug.
Over the next three years, each of the grant recipients will receive $50,000 from the NACDS Foundation to support the development of a residency position for graduates of accredited schools and colleges of pharmacy.
Established in 2010, Community PREP seeks to create 30 new, fully accredited post-graduate year-one community pharmacy residency opportunities through grants to nonprofit pharmacy schools and colleges. The grants are designed to foster the creation or expansion of a patient-focused residency program, where a faculty member or preceptor will oversee the selected pharmacy resident’s learning experience at a pharmacy practice site. Grant recipients are determined based on the recommendations of an independent review committee comprised of representatives from the American Association of College of Pharmacy, the American Pharmacists Association and the NACDS Foundation.
“The Community PREP grant program was developed to provide expanded opportunities for pharmacy school graduates to pursue community pharmacy residencies and hone their skills in providing patient care services,” NACDS Foundation president Edith Rosato said. “I commend these three prestigious recipients for their dedication to patient care and their laudable commitment to mentoring the next generation of pharmacy graduates.”
Community PREP grant applications are accepted on a continuing basis, with a deadline of July 1. Twelve additional grants will be awarded in 2011, and another 15 will be awarded in 2012.
Teva to market generic Combivir tablets
JERUSALEM — Teva Pharmaceutical Industries is set to market a generic version of an HIV treatment, the drug maker announced Thursday.
Teva said it will launch generic Combivir tablets (lamivudine and zidovudine) and is eligible for a 180-day period of marketing exclusivity, according to the Food and Drug Administration. The drug maker is expected to ship the drug in fourth quarter 2011, per terms of a settlement agreement between Teva, Glaxo Group and ViiV Healthcare.
Combivir tablets had annual sales of approximately $315 million in the United States, according to IMS sales data.
Retail pharmacy should be applauded for emphasizing medication adherence
WHAT IT MEANS AND WHY IT’S IMPORTANT — The fact that CVS Caremark convened its first-ever national forum in an effort to battle the $300 billion problem of medication nonadherence is important on several fronts, including the simple fact that retail pharmacy deserves credit for more effectively communicating what adherence is and why it’s important.
(THE NEWS: CVS Caremark convenes first-ever national forum on nonadherence. For the full story, click here.)
Such efforts as this forum — which uncoincidentally was held at the National Press Club in Washington, D.C. — are an important reason why consumer awareness is rising on the importance of adherence. So are such programs as the Script Your Future campaign, which kicked off May 23 in Providence, R.I.
As reported by Drug Store News, Elizabeth Roberts, lieutenant governor of the state of Rhode Island, together with the National Consumers League launched Script Your Future in Providence to raise awareness among patients about the health consequences of not taking medication as directed. CVS Caremark, a national partner in the Script Your Future campaign, is headquartered in Rhode Island and participated in the Providence launch, which is 1-of-6 regional city markets where the campaign will pilot activities, research and advertising.
Both the forum and the campaign launch were offered online as a webcast, making it yet one more indication of the effort to spread the word and raise awareness on the vexing issue of nonadherence.
Nonadherence is not only a $300 billion a year drain on the U.S. healthcare system, but the stark reality is that it also is a matter of life and death. More than one-third of medicine-related hospitalizations and nearly 125,000 deaths in the United States each year are due to people not taking their medicines as directed.